AorTech and SynCardia in artificial heart pact
This article was originally published in Clinica
Executive Summary
SynCardia Systems is to use AorTech International’s Elast-Eon polymer heart valve in its temporary artificial heart technology after the two firms signed an exclusive licensing and supply agreement. According to Surbiton, UK-based AorTech, its valve has been shown to be more durable than biologic valves with comparable haemodynamic characteristics. SynCardia (Tucson, Arizona) will pay AorTech $2.1m over an 18-month period, with minimum valve purchases and volume-related discounts. The heart-assist device sector could reach a market value of $8-10bn within the coming decade, claims AorTech. SynCardia plans to submit the valve for CE mark and FDA approval in the second half of 2010.